Treatment with rivaroxaban compared with warfarin in patients with acute coronary syndrome

Evaluation of the effect of rivaroxaban treatment in comparison with warfarin on the resolution, size, mobility and morphology of left ventricular apical thrombus and also comparing the incidence of bleeding, readmission, embolic events and cardiovascular events in patients with acute coronary syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210614051574N9

Enrollment

Registered

2022-02-19

Start date

2022-03-03

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome. Other acute ischemic heart diseases

Interventions

Intervention 1: Intervention group 1: In this group, patients undergo echocardiography and after the initial anticoagulant treatment, rivaroxaban 15 mg tablets from Abureyhan Company will be used ever

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Acute coronary syndrome Treated with aspirin and Plavix

Exclusion criteria

Exclusion criteria: Renal and hepatic failure Existence of contraindications to anticoagulant therapy Major trauma Uncontrolled hypertension

Design outcomes

Primary

Measure	Time frame
Left ventricular morphology information. Timepoint: 3 months after starting the study. Method of measurement: Eco cardiography.;Bleeding. Timepoint: 3 months after starting the study. Method of measurement: Review the case and follow up with the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hadi Mansouri

Esfahan University of Medical Sciences

parsa.alinezhad85@gmail.com+98 31 3668 0042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026